The FDA approval follows a successful Canadian launch in July, positioning XERF as a central part of Cynosure Lutronic’s U.S. market strategy. It is the first product introduced since the merger of Cynosure and Lutronic and will make its official debut at the Cynosure Lutronic Academy global conference in September in Miami.
XERF employs a dual-frequency system (6.78 MHz and 2 MHz) with three adjustable depth settings for treatment customization. It also incorporates a patent-pending 'Spider Pattern' technology to expand treatment coverage within a single session. A built-in cooling mechanism reduces discomfort and minimizes the need for separate anesthesia.
“Cynosure Lutronic has reached a significant milestone with this FDA clearance, marking a pivotal step in our North American expansion,” said Nadav Tomer, CEO of Cynosure Lutronic. “We are thrilled to offer medical professionals and patients a new standard in radiofrequency treatments.”

The company noted that the FDA clearance validates XERF’s safety and efficacy. “TThis approval underscores the device’s reliability and performance,” a Cynosure Lutronic spokesperson said. “We are committed to further expanding regulatory approvals and strengthening our global customer network.”
XERF is already available in markets including South Korea, Canada, Japan, Hong Kong, and Singapore. By year’s end, the company plans to expand into the U.S., Brazil, and Thailand, responding to rising global demand for advanced aesthetic and medical RF technologies.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr